Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Details

Serval ID
serval:BIB_2BF0DD8008FD
Type
Article: article from journal or magazin.
Collection
Publications
Title
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
Journal
Alzheimer's & dementia
Author(s)
Mattsson N., Groot C., Jansen W.J., Landau S.M., Villemagne V.L., Engelborghs S., Mintun M.M., Lleo A., Molinuevo J.L., Jagust W.J., Frisoni G.B., Ivanoiu A., Chételat G., Resende de Oliveira C., Rodrigue K.M., Kornhuber J., Wallin A., Klimkowicz-Mrowiec A., Kandimalla R., Popp J., Aalten P.P., Aarsland D., Alcolea D., Almdahl I.S., Baldeiras I., van Buchem M.A., Cavedo E., Chen K., Cohen A.D., Förster S., Fortea J., Frederiksen K.S., Freund-Levi Y., Gill K.D., Gkatzima O., Grimmer T., Hampel H., Herukka S.K., Johannsen P., van Laere K., de Leon M.J., Maier W., Marcusson J., Meulenbroek O., Møllergård H.M., Morris J.C., Mroczko B., Nordlund A., Prabhakar S., Peters O., Rami L., Rodríguez-Rodríguez E., Roe C.M., Rüther E., Santana I., Schröder J., Seo S.W., Soininen H., Spiru L., Stomrud E., Struyfs H., Teunissen C.E., Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G., Wallin Å.K., Wiltfang J., Vandenberghe R., Brooks D.J., Fladby T., Rowe C.C., Drzezga A., Verbeek M.M., Sarazin M., Wolk D.A., Fleisher A.S., Klunk W.E., Na D.L., Sánchez-Juan P., Lee D.Y., Nordberg A., Tsolaki M., Camus V., Rinne J.O., Fagan A.M., Zetterberg H., Blennow K., Rabinovici G.D., Hansson O., van Berckel BNM, van der Flier W.M., Scheltens P., Visser P.J., Ossenkoppele R.
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Publication state
Published
Issued date
07/2018
Peer-reviewed
Oui
Volume
14
Number
7
Pages
913-924
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.
We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location.
The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education.
The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
Keywords
Aged, Alleles, Alzheimer Disease/metabolism, Amyloid beta-Peptides/metabolism, Apolipoprotein E4/genetics, Biomarkers/cerebrospinal fluid, Cognitive Dysfunction/metabolism, Europe, Female, Humans, Male, Positron-Emission Tomography, Prevalence, APOE, Age, Alzheimer's disease, Amyloid, CSF, Education, Geographical location, Mild cognitive impairment, PET, Sex, Subjective cognitive decline
Pubmed
Web of science
Create date
03/04/2018 14:07
Last modification date
20/08/2019 14:11
Usage data